Kyselina Zoledrónová Sandoz (Zoledronic Acid Monohydrate)

Zoledronic acid binds to hydroxyapatite at active bone remodeling sites and is taken up by osteoclasts. Inside the cell it blocks the enzyme farnesyl pyrophosphate synthase in the mevalonate pathway, preventing prenylation of essential proteins, which leads to osteoclast apoptosis and a decrease in bone resorption.

The dosing regimen for Kyselina Zoledrónová Sandoz is determined by the prescribing clinician based on the specific indication, patient weight, renal function and other clinical factors. The product is supplied as a sterile intravenous solution and should be administered only under medical supervision according to the prescriber's instructions.

Zoledronic acid is classified as contraindicated in pregnancy because it can cross the placenta and affect fetal bone development. It is also not recommended while breastfeeding, as it may be secreted in milk. Women of child‑bearing potential should use effective contraception during treatment and discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where applicable) and any necessary import documentation.

Zoledronic acid is a more potent, third‑generation bisphosphonate that can be given as a single annual or quarterly intravenous infusion, whereas older agents such as alendronate or risedronate require daily or weekly oral dosing. This dosing convenience can improve adherence, but intravenous administration requires medical supervision and monitoring for renal safety.

Kyselina Zoledrónová Sandoz should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Do not freeze the solution. Before use, inspect the vial for any particulate matter or discoloration and handle it with aseptic technique as recommended for intravenous preparations.

The medication is supplied as a sterile intravenous solution that is infused over a period of 15 minutes to several hours, depending on the dose and clinical protocol. Administration must be performed by qualified healthcare personnel in a setting equipped for intravenous therapy, with appropriate monitoring of vital signs and renal function.

The most critical adverse events to monitor are renal toxicity, which can be irreversible if not detected early; osteonecrosis of the jaw, especially after dental extractions; and severe hypocalcemia, which may cause cardiac arrhythmias or seizures. Prompt assessment of renal function and calcium levels before each infusion helps mitigate these risks.

Patients with severe renal impairment (creatinine clearance <30 mL/min), known hypersensitivity to zoledronic acid or any component of the formulation, active dental or jaw infections, and pregnant or nursing women should not receive this medication. Clinicians should also exercise caution in individuals with low serum calcium or vitamin D deficiency.